ReviewJournal of clinical medicine2015
MicroRNAs as Signaling Mediators and Biomarkers of Drug- and Chemical-Induced Liver Injury.
Review in Journal of clinical medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Circulating miRNAs as Novel Diagnostic Biomarkers in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Canadian journal of gastroenterology & hepatology · 2019Pooled it
- Biomarkers of Hepatic Toxicity: An Overview.Current therapeutic research, clinical and experimental · 2024Review
- Article
- MiRNAs as Potential Regulators of Enthesis Healing: Findings in a Rodent Injury Model.International journal of molecular sciences · 2023Article
- Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues.Annals of translational medicine · 2021Review
- miR-15a-3p Protects Against Isoniazid-Induced Liver InjuryFrontiers in molecular biosciences · 2021Article
- Review
- Diagnostic Biomarkers in Liver Injury by Drugs, Herbs, and Alcohol: Tricky Dilemma after EMA Correctly and Officially Retracted Letter of Support.International journal of molecular sciences · 2019Review
- miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis.International journal of molecular sciences · 2018Review
- Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation.Expert review of molecular diagnostics · 2018Review
- Plasma Micro-RNA Alterations Appear Late in Pancreatic Cancer.Annals of surgery · 2018Article
- Models of Drug Induced Liver Injury (DILI) - Current Issues and Future Perspectives.Current drug metabolism · 2018Review
- Effects of oral implants with miR‑122‑modified cell sheets on rat bone marrow mesenchymal stem cells.Molecular medicine reports · 2018Article
- Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?International journal of molecular sciences · 2017Review
- Modulation of miR-26a-5p and miR-15b-5p Exosomal Expression Associated with Clopidogrel-Induced Hepatotoxicity in HepG2 Cells.Frontiers in pharmacology · 2017Article
- Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.World journal of gastroenterology · 2016Observational
- Clinical characteristics of drug-induced liver injury and related risk factors.Experimental and therapeutic medicine · 2016Article
- Review
- Human Ex-Vivo Liver Model for Acetaminophen-induced Liver Damage.Scientific reports · 2016Article
- Traditional Chinese Medicine (TCM) and Herbal Hepatotoxicity: RUCAM and the Role of Novel Diagnostic Biomarkers Such as MicroRNAs.Medicines (Basel, Switzerland) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Drug-induced liver injury (DILI) is major problem for both the drug industry and for clinicians. There are two basic categories of DILI: intrinsic and idiosyncratic. The former is the chief cause of acute liver failure in several developed countries, while the latter is the most common reason for post-marketing drug withdrawal and a major reason for failure to approve new drugs in the U.S. Although considerably more progress has been made in the study of intrinsic DILI, our understanding of both forms of drug hepatotoxicity remains incomplete. Recent work involving microRNAs (miRNAs) has advanced our knowledge of DILI in two ways: (1) possible roles of miRNAs in the pathophysiological mechanisms of DILI have been identified, and (2) circulating miRNA profiles have shown promise for the detection and diagnosis of DILI in clinical settings. The purpose of this review is to summarize major findings in these two areas of research. Taken together, exciting progress has been made in the study of miRNAs in DILI. Possible mechanisms through which miRNA species contribute to the basic mechanisms of DILI are beginning to emerge, and new miRNA-based biomarkers have the potential to greatly improve diagnosis of liver injury and prediction of patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.